September 22, 2023
Bulletin interne de l'Institut Pasteur
Development of an onco-therapeutic vaccine candidate against human papillomavirus (HPV)-induced cancers, based on preclinical results showing 100% efficacy
The Biotech TheraVectys, in collaboration with Institut Pasteur-TheraVectys Joint Laboratory, has just demonstrated the preclinical efficacy of its "Lenti-HPV-07" lentiviral vector-based vaccine candidate, administered intramuscularly, against cervical and oropharyngeal cancers induced by human papillomavirus (HPV). These results were published in EMBO Molecular Medicine journal, in an article entitled "Full eradication of pre-clinical human papilloma virus induced tumors by a lentiviral vaccine".